A Randomized, Controlled, Phase I Study of Fecal Microbiota Transplant and Dietary Fiber Supplementation in Graft Versus Host Disease

Who is this study for? Patients with graft-versus-host disease
Status: Recruiting
Location: See location...
Intervention Type: Procedure, Other, Biological, Dietary supplement
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This phase I trial studies how well fecal microbiota transplant and dietary fiber supplementation work in treating patients with gut graft versus host disease. Fecal microbiota transplant entails inoculating donor stool into a recipient's gastrointestinal tract. Changing the gut microbiome by fecal microbiota transplant and fiber supplementation may help treat gut graft versus host disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years of age or older

• History of allogeneic hematopoietic stem cell transplant in the past 365 days

• Post-engraftment, defined by time period following three consecutive days of sustained neutrophil engraftment with an absolute neutrophil count of at least 500 cells/mm\^3

• Mild to severe acute GI GvHD, at least stage 1, as measured by one of the following:

‣ Modified Glucksberg criteria for GI GvHD averaged over 3 consecutive days and without another explanation for diarrhea such as laxative use or infection. In patients who have already had GI biopsy, biopsy histology must be compatible with GVHD, although biopsy is not required

⁃ Biopsy evidence of GI GVHD in the upper or lower GI tract

Locations
United States
Washington
Fred Hutch/University of Washington Cancer Consortium
RECRUITING
Seattle
Contact Information
Primary
David Fredricks
dfredric@fredhutch.org
206.667.1935
Time Frame
Start Date: 2025-01-24
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 72
Treatments
Experimental: Arm I (upper FMT)
Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Experimental: Arm II (Lower FMT)
Patients undergo lower FMT via colonoscopy on day 0. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Experimental: Arm III (upper FMT, fiber supplementation)
Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from the first day of FMT administration and up to 6 weeks post FMT. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Experimental: Arm IV (Lower FMT, fiber supplementation)
Patients undergo lower FMT via colonoscopy on day 0. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from day 0 up to 6 weeks post FMT. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
Sponsors
Leads: Fred Hutchinson Cancer Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)

This content was sourced from clinicaltrials.gov